AU2014317048B2 - Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors - Google Patents

Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors Download PDF

Info

Publication number
AU2014317048B2
AU2014317048B2 AU2014317048A AU2014317048A AU2014317048B2 AU 2014317048 B2 AU2014317048 B2 AU 2014317048B2 AU 2014317048 A AU2014317048 A AU 2014317048A AU 2014317048 A AU2014317048 A AU 2014317048A AU 2014317048 B2 AU2014317048 B2 AU 2014317048B2
Authority
AU
Australia
Prior art keywords
compound
acid
alkyl
pharmaceutically
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014317048A
Other languages
English (en)
Other versions
AU2014317048A1 (en
Inventor
Conni Lauritzen
John Pedersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuprozyme Therapeutics ApS
Original Assignee
Neuprozyme Therapeutics ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuprozyme Therapeutics ApS filed Critical Neuprozyme Therapeutics ApS
Publication of AU2014317048A1 publication Critical patent/AU2014317048A1/en
Application granted granted Critical
Publication of AU2014317048B2 publication Critical patent/AU2014317048B2/en
Assigned to Neuprozyme Therapeutics ApS reassignment Neuprozyme Therapeutics ApS Request for Assignment Assignors: PROZYMEX A/S
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2014317048A 2013-09-09 2014-09-08 Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors Active AU2014317048B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13183519 2013-09-09
EP13183519.1 2013-09-09
EP14151979.3 2014-01-21
EP14151979 2014-01-21
PCT/EP2014/069088 WO2015032945A1 (en) 2013-09-09 2014-09-08 Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors

Publications (2)

Publication Number Publication Date
AU2014317048A1 AU2014317048A1 (en) 2016-04-07
AU2014317048B2 true AU2014317048B2 (en) 2018-05-10

Family

ID=51535425

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014317048A Active AU2014317048B2 (en) 2013-09-09 2014-09-08 Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors

Country Status (10)

Country Link
US (1) US9856228B2 (OSRAM)
EP (1) EP3044214B1 (OSRAM)
JP (1) JP6408008B2 (OSRAM)
CN (1) CN105612149A (OSRAM)
AU (1) AU2014317048B2 (OSRAM)
CA (1) CA2923484C (OSRAM)
DK (1) DK3044214T3 (OSRAM)
EA (1) EA029030B1 (OSRAM)
SG (1) SG11201601150WA (OSRAM)
WO (2) WO2015032943A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6408008B2 (ja) 2013-09-09 2018-10-17 プロザイメックス・アクティーゼルスカブＰｒｏＺｙｍｅｘ Ａ／Ｓ ジペプチジルペプチダーゼｉインヒビターとしてのペプチジルニトリル化合物
NO2699580T3 (OSRAM) 2014-01-24 2018-02-24
DK3265452T3 (en) * 2015-03-05 2020-06-08 Neuprozyme Therapeutics ApS Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
DK3280401T3 (da) 2015-04-07 2021-11-15 Ela Pharma Ltd Sammensætninger til behandling og/eller forebyggelse af celle- eller vævsnekrose specielt rettet mod kathepsin c og/eller cela1 og/eller cela3a og/eller strukturelt relaterede enzymer dertil
PL3758708T3 (pl) 2018-03-01 2025-03-31 Astrazeneca Ab Kompozycje farmaceutyczne zawierające (2s)-{(1s)-1-cyjano-2-[4-(3-metylo-2-okso-2,3-dihydro-1,3-benzoksazol-5-ilo)fenylo]etylo}-1,4-oksazepano-2-karboksyamid
US11998553B2 (en) 2018-07-17 2024-06-04 Insmed Incorporated Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
WO2022020245A1 (en) 2020-07-20 2022-01-27 Insmed, Inc. Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions
TW202413352A (zh) 2022-06-13 2024-04-01 日商模數探索股份有限公司 氮雜環烷基羰基環狀胺化合物
IL321931A (en) 2023-01-06 2025-09-01 Insmed Inc New and reversible DPP1 inhibitors and their uses
WO2025162472A1 (en) * 2024-01-31 2025-08-07 Insmed Incorporated Linear dipeptidyl peptidase 1 inhibitors and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012119941A1 (en) * 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902181B2 (en) * 2007-12-12 2011-03-08 Astrazeneca Ab Compounds 010
KR100903499B1 (ko) 2007-12-27 2009-06-18 엔에이치엔비즈니스플랫폼 주식회사 검색 의도 분류에 따른 광고 제공 방법 및 상기 방법을수행하기 위한 시스템
AU2010244218B2 (en) 2009-05-07 2012-07-19 Astrazeneca Ab Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750
WO2010142985A1 (en) * 2009-06-10 2010-12-16 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
WO2011154677A1 (en) 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
WO2012130299A1 (en) 2011-03-30 2012-10-04 Prozymex A/S Peptidase inhibitors
US8999975B2 (en) 2011-09-19 2015-04-07 Boehringer Ingelheim International Gmbh Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
JP6408008B2 (ja) 2013-09-09 2018-10-17 プロザイメックス・アクティーゼルスカブＰｒｏＺｙｍｅｘ Ａ／Ｓ ジペプチジルペプチダーゼｉインヒビターとしてのペプチジルニトリル化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012119941A1 (en) * 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors

Also Published As

Publication number Publication date
WO2015032945A1 (en) 2015-03-12
US9856228B2 (en) 2018-01-02
EA029030B1 (ru) 2018-01-31
CA2923484C (en) 2022-09-06
DK3044214T3 (da) 2017-11-13
JP6408008B2 (ja) 2018-10-17
EP3044214A1 (en) 2016-07-20
NZ718128A (en) 2021-04-30
EP3044214B1 (en) 2017-08-09
AU2014317048A1 (en) 2016-04-07
CA2923484A1 (en) 2015-03-12
WO2015032943A1 (en) 2015-03-12
SG11201601150WA (en) 2016-03-30
JP2016529306A (ja) 2016-09-23
EA201690561A1 (ru) 2016-07-29
CN105612149A (zh) 2016-05-25
US20160207900A1 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
AU2014317048B2 (en) Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors
US10479781B2 (en) Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors
US12172974B2 (en) Prodrugs of riluzole and their method of use
WO2012119941A1 (en) Peptidyl nitrilcompounds as peptidase inhibitors
US20110269834A1 (en) Compounds and methods for treating respiratory diseases
WO2015032942A1 (en) N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
CN102596321B (zh) 可用作dpp-1抑制剂的炔基衍生物
MX2011011139A (es) Antagonistas ccr3 arisulfonamida 2, 5-disustituidos.
WO2016139355A1 (en) N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
WO2012130299A1 (en) Peptidase inhibitors
US9187461B2 (en) Cathepsin C inhibitors
EP4341252A1 (en) Oxoindoline compound for the treatment of inflammatory diseases or cancer
US7683093B2 (en) Prolinyl derivatives for the treatment of thrombosis
NZ718128B2 (en) Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
WO2012112733A1 (en) Cathepsin c inhibitors
NZ614540B2 (en) Cathepsin c inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NEUPROZYME THERAPEUTICS APS

Free format text: FORMER OWNER(S): PROZYMEX A/S